DrugBiological
Caxmotabart entudotin clinical trials
Keep track of what changes. Save the caxmotabart entudotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStudies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · Iksuda Therapeutics Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses caxmotabart entudotin is read from its arms, and is right about nine times in ten.
Testing it · 3
- IKS014 in Advanced Solid Tumors That Express HER2RecruitingPhase 1Iksuda Therapeutics Ltd.NCT05872295Written as IKS014
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT05755048Written as Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
- Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.CompletedPhase 1Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT03944499Written as FS-1502
Codes
What other systems call caxmotabart entudotin · ClinicalTrials.gg INT017313
- UNII (FDA) MNX9BG4BZKCAXMOTABART ENTUDOTINOne source FDA
- NCI Thesaurus C172821Caxmotabart EntudotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MNX9BG4BZK | CAXMOTABART ENTUDOTIN | One source FDA |
| NCI Thesaurus | C172821 | Caxmotabart Entudotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.